• Evidence suggests that certain types of plaques have a higher risk of CVD within ~3-6 months. For such plaques, medications such as sglt2 inhibitors, pcsk9 inhibitors, statins, and anti-platelets have demonstrated the ability to alter the plaque characteristics and prevent any critical event.
• qVH helps identify asymptomatic patients with such plaque characteristics and estimates a dynamic CVD risk score that helps manage the patient’s health with different treatment protocols.